NCCN Guidelines® Version 1.2026 (March 11, 2026)— Prevention and Treatment of Cancer-Related Infections, IDSA Guidelines | Evidence-Based Medicine | Clinical Trials
OVERVIEW & CLASSIFICATION OF FUNGAL PATHOGENS
1.1 Why Fungal Infections Matter in Hem/Onc
Fungal infections carry high morbidity and mortality in immunocompromised oncology patients.
Risk arises from the malignancy itself AND from antineoplastic therapies (chemotherapy, targeted agents, immunotherapy, HCT).
NCCN recognizes neutropenia as the major risk factor; however, non-neutropenic immunosuppressed states (e.g., GVHD, CAR-T) carry equal or greater risk.
The spectrum of organisms has shifted: increased voriconazole use has been associated with emerging Mucorales infections (breakthrough mucormycosis).
KEY NUANCES: Risk Stratification • AML/MDS on induction: Posaconazole is the ONLY Category 1 mold-active prophylaxis agent — do not substitute without good reason. • Autologous HCT WITHOUT mucositis: No antifungal prophylaxis. Do NOT add prophylaxis reflexively. • CYP3A4 concern: When vincristine or proteasome inhibitors are co-administered, switch from mold-active azoles (especially POS/VOR) to echinocandin or AmB prophylactic doses. • Post-engraftment GVHD on IST is often more immunocompromised than the neutropenic phase — maintain/extend mold-active prophylaxis. • Categories of risk depend on: underlying malignancy, remission status, neutropenia duration, prior chemo, CMV serostatus, IST intensity.
Oral thrush: white plaques on buccal mucosa, tongue, palate — scrapable off leaving erythema
Esophageal candidiasis: odynophagia, dysphagia — often without visible oral thrush
Cutaneous: erythematous rash in skin folds (intertriginous), satellite lesions
3.1b Invasive Candidiasis / Candidemia
Fever unresponsive to broad-spectrum antibiotics — hallmark
Hemodynamic instability, septic shock
Endophthalmitis: blurred vision, eye pain (seen in ~5–10% of candidemia — ophthalmology exam mandatory)
Hepatosplenic candidiasis (chronic disseminated): fever + elevated ALP + bull’s-eye lesions on CT/MRI liver & spleen — classically seen in AML after neutrophil recovery
3.2 Invasive Aspergillosis (IA)
Pulmonary: fever, cough, pleuritic chest pain, hemoptysis — often presenting like antibiotic-unresponsive pneumonia
Sinus/rhinosinusitis: facial pain, nasal congestion/discharge, periorbital swelling — can progress to orbital/CNS extension
CT chest: nodule with halo sign (early), air crescent sign (late/during recovery), wedge-shaped infarcts — classic but not pathognomonic
3.3 Mucormycosis
Rhinocerebral form (most common in neutropenic/DM): black eschar on nasal mucosa or palate, periorbital edema, proptosis, facial numbness, ophthalmologic findings → rapidly fatal if untreated
Pulmonary: similar to IA but more rapid progression; CT shows reverse halo sign (more specific)
Disseminated: can occur in severely immunocompromised; high mortality
Histopathology: broad, ribbon-like, aseptate (pauci-septate) hyphae with 90-degree branching — contrasts with Aspergillus (narrow, septate, 45-degree branching)
3.4 Differential Diagnosis
Clinical Scenario
Top Differentials
Key Distinguishing Features
Fever + new pulmonary infiltrate in neutropenic patient
~70% sens / ~89% spec for proven IA (NCCN) Reduced by mold-active antifungal prophylaxis
False positive: piperacillin-tazobactam (current US formulations rarely — but check!), children, allo-HCT. Mold-active azoles/echinocandins DECREASE sensitivity significantly. Serial monitoring preferred over single values.
BAL Galactomannan
Aspergillus (pulmonary)
Higher sensitivity than serum GM for pulmonary IA
Cutoff typically ≥1.0 ODI for BAL vs ≥0.5 for serum. More useful than serum in pulmonary disease.
False positives: IV amoxicillin-clavulanate, surgical packing, IVIG, albumin, dialysis membranes. NEGATIVE in mucormycosis and cryptococcosis — use to narrow DDx.
Histoplasma Urine/Serum Antigen
Histoplasma capsulatum
High sensitivity for disseminated disease
Useful in endemic areas (central US). Cross-reacts with Blastomyces.
Cryptococcal Antigen (CrAg)
Cryptococcus neoformans/gattii
Highly sensitive and specific
Serum or CSF. Point-of-care lateral flow assay available.
Aspergillus PCR
Aspergillus DNA
Emerging; not yet standard of care
Can complement galactomannan. Higher sensitivity but lower specificity.
4.3 Imaging
CT Chest (high-resolution): preferred over CXR for pulmonary IFI. CXR misses early lesions.
Halo sign: ground-glass opacity surrounding a nodule → classic for early IA (not specific — also seen in other angioinvasive fungi).
Air-crescent sign: late sign of IA, appears during neutrophil recovery as necrotic tissue separates.
Reverse halo / atoll sign: central ground-glass with peripheral dense rim → more associated with Mucorales (not specific).
CT sinuses/MRI brain/orbits: for rhinocerebral disease — mandatory when black eschar present.
CT abdomen: bull’s-eye lesions in liver/spleen → hepatosplenic candidiasis.
NCCN Guideline: Galactomannan Surveillance Recommendation • For high-risk patients (prolonged neutropenia, allo-HCT) with clinical/radiologic findings compatible with IA (new pulmonary nodule ≥1 cm, new infiltrate) + positive serum galactomannan → treat as probable IA with mold-active agent (voriconazole preferred). • Sensitivity of GM is significantly REDUCED by concomitant mold-active antifungal agents. If patient is already on VOR/POS prophylaxis, GM may be falsely negative. • Mucormycosis: NEGATIVE serum galactomannan AND beta-glucan — presence of these negative results in a sick patient with sinus disease should raise suspicion for Mucor, NOT reassure.
ANTIFUNGAL PHARMACOTHERAPY REFERENCE GUIDE
Based on NCCN FEV-B (Antifungal Agents Tables) Version 1.2026
5.1 AZOLES
Class Note: Azoles inhibit ergosterol synthesis via CYP51 (14-alpha-demethylase). All azoles EXCEPT isavuconazole prolong QTc. All mold-active azoles are potent CYP3A4 inhibitors.
TDM: Routinely used for itraconazole, posaconazole, voriconazole. NOT routinely used for isavuconazole or fluconazole (NCCN FEV-B 1 of 5).
Active: most Candida spp., Cryptococcus Inactive: Molds (Aspergillus, Mucorales), C. glabrata (reduced susceptibility), C. krusei (intrinsically resistant)
Renal: reduce dose for CrCl <50 (use 50% dose) Hepatic: use with caution; not extensively studied HD: dose after dialysis
• Least potent CYP3A4 inhibitor among azoles (NCCN) • Candida susceptibility testing recommended • Avoid in C. krusei (intrinsic resistance) and C. glabrata without susceptibility testing • QTc prolongation possible
Itraconazole
Prophylaxis/treatment: 200 mg PO BID (solution preferred) IV: 200 mg IV BID x 2 days, then 200 mg IV daily
Hepatic: contraindicated in severe hepatic impairment Renal: IV formulation contains cyclodextrin — avoid if CrCl <30 (accumulation of cyclodextrin vehicle) No dose adjustment for capsules
• NEGATIVE INOTROPIC effects — avoid in HF (itraconazole capsules/IV) • Solution formulation preferred (better bioavailability — take fasting) • Capsule requires ACID environment — antacids/PPIs/H2 blockers DECREASE absorption • SUBA-itraconazole has improved absorption but is NOT interchangeable with other itraconazole formulations • TDM: trough target 0.5–1 mg/L (prophylaxis), 1–4 mg/L (treatment)
Posaconazole
Prophylaxis (AML/MDS, GVHD): • DR tablet: 300 mg PO BID x 2 doses (Day 1 loading), then 300 mg PO daily • IV: 300 mg IV BID x 2 doses (Day 1), then 300 mg IV daily • Oral suspension: 200 mg PO TID (with high-fat meal) Treatment (refractory/intolerant of AmB): • Same dosing as above
Active: Candida, Aspergillus, MUCORALES (Rhizopus, Mucor), Fusarium, dimorphic fungi Good mold coverage distinguishes it from fluconazole/itraconazole
Hepatic: use with caution; monitor LFTs Renal: IV formulation contains vehicle (SBECD) — avoid if CrCl <50 (use PO instead) No PO dose adjustment for renal impairment
• PPIs DECREASE posaconazole oral suspension plasma concentrations (less of an issue with DR tablet and IV) • DR tablet preferred over oral suspension for prophylaxis due to improved bioavailability and less food interaction • Oral suspension requires HIGH-FAT MEAL or carbonated beverage for absorption • TDM: trough target ≥700 ng/mL (prophylaxis), ≥1000 ng/mL (treatment) • FDA-approved for prophylaxis in AML/MDS induction and GVHD (Cat 1)
Voriconazole
IA primary treatment: • IV: 6 mg/kg IV q12h x 2 doses (loading), then 4 mg/kg IV q12h (maintenance) • PO: loading 400 mg q12h x 2 doses, then 200–300 mg PO BID Candidemia (non-neutropenic): • Loading 6 mg/kg IV BID x 2 doses, then 3–4 mg/kg IV BID • OR oral: ≥40 kg: 200 mg BID; <40 kg: 100 mg BID
Active: Candida, Aspergillus spp. (NOT A. terreus), dimorphic fungi, C. neoformans Poor: Mucorales (NO activity — MAJOR WATCHOUT) Active against invasive aspergillosis and mucormycosis… NO — ONLY aspergillosis
Hepatic: reduce maintenance dose in mild-moderate hepatic impairment; avoid severe Renal: IV formulation contains SBECD vehicle — avoid if CrCl <50 (accumulation of cyclodextrin). Use PO voriconazole instead No PO dose adjustment for renal impairment
• Standard of care (Category 1) for primary therapy of invasive aspergillosis • HIGH inter-individual PK variability → TDM strongly recommended • TDM trough target: 1–5.5 mcg/mL; obtain 1 week after initiating therapy • <1 mcg/mL: disease progression risk; >5.5 mcg/mL: neurotoxicity, hepatotoxicity risk • ZERO activity against Mucorales — voriconazole prophylaxis may UNMASK or select for Mucorales breakthrough infections • Adverse effects: visual disturbances (photopsia, chromatopsia), hallucinations, peripheral neuropathy, QTc prolongation (use with caution), periostitis/fluorosis with long-term use, increased SCC skin risk • Significant CYP2C19 polymorphism → East Asians are poor metabolizers (higher levels); dose accordingly
Hepatic: avoid in severe hepatic impairment Renal: No dose adjustment; IV formulation does NOT contain SBECD — safe in CrCl <50 No PO dose adjustment for renal
• UNIQUE: does NOT prolong QTc — actually SHORTENS QTc (use when QTc prolongation is concern with other azoles) • TDM: not routinely required (NCCN FEV-B 1 of 5) • FDA-approved for IA (non-inferior to VOR, SECURE trial) AND invasive mucormycosis • Less hepatotoxic profile than VOR • No food restriction; better oral bioavailability than itraconazole/posaconazole oral suspension • Water-soluble: no cyclodextrin vehicle → safe in renal impairment via IV
5.2 AMPHOTERICIN B FORMULATIONS
Class Note: Binds ergosterol → disrupts membrane integrity. Broadest antifungal spectrum. Lipid formulations preferred for reduced toxicity (NCCN Cat 1 preference over AmB-D).
Formulation
Dose
Spectrum
Key Cautions & Pharmacist Notes
Amphotericin B Deoxycholate (AmB-D) [Conventional]
0.5–1.5 mg/kg IV daily (indication-dependent)
Broad: Candida (most spp.), Aspergillus (NOT A. terreus), Mucorales, Cryptococcus, dimorphic fungi Intrinsic resistance: Scedosporium, Lomentospora, some Candida lusitaniae
• NOT preferred whenever L-AMB or ABLC is available (NCCN) • Major nephrotoxicity: acute tubular necrosis, renal wasting (K, Mg) • Infusion reactions: fever, chills, rigors, nausea → premedicate with APAP, diphenhydramine, hydrocortisone; meperidine for rigors • Saline loading (1L NS before infusion) reduces nephrotoxicity • Never add to dextrose-containing solution with NaCl or KCl (compatibility) • Monitor K+, Mg2+, Cr, BUN daily
Amphotericin B Lipid Complex (ABLC) [Abelcet®]
5 mg/kg IV daily
Same as AmB-D
• Lipid complex formulation → less renal toxicity than AmB-D • Infusion-related reactions still occur (less than AmB-D) • Premedication still recommended • Filter (5-micron) required; shake well • Monitor electrolytes (K+, Mg2+) and renal function
Liposomal Amphotericin B (L-AmB) [AmBisome®]
3–5 mg/kg IV daily Aspergillosis: 3 mg/kg = same efficacy as 10 mg/kg (AmBiLoad trial) with less toxicity (NCCN FEV-B note e) Mucormycosis: 5 mg/kg (higher dose may be needed per other literature)
Same as AmB-D
• Most preferred formulation: best nephrotoxicity profile • Less infusion reactions than AmB-D or ABLC • Still monitor K+, Mg2+, Cr • AmBiLoad trial: 3 mg/kg vs 10 mg/kg — no efficacy difference but significantly more toxicity at higher dose • For mucormycosis, 5 mg/kg commonly used; some centers titrate higher • Reconstitute in D5W (NOT saline — causes precipitation)
5.3 ECHINOCANDINS
Class Note: Inhibit (1,3)-beta-D-glucan synthase → disrupts fungal cell wall. Fungicidal vs Candida, fungistatic vs Aspergillus. Excellent safety profile. NCCN: three classic agents considered interchangeable. Rezafungin is newer (once-weekly dosing).
Agent
Dose
Spectrum
Key Pharmacist Notes
Anidulafungin [Eraxis®]
Candidemia/invasive candidiasis: 200 mg IV loading x 1 dose, then 100 mg IV daily Candidal esophagitis: 100 mg IV loading, then 50 mg IV daily
• NO hepatic dose adjustment (no hepatic metabolism — degraded by non-enzymatic degradation) • NO renal dose adjustment • Fewest drug interactions of the echinocandins • Compatible with most IV solutions
Caspofungin [Cancidas®]
Empiric therapy (neutropenic fever): 70 mg IV loading, then 50 mg IV daily Candidemia: 70 mg IV loading, then 50 mg IV daily Aspergillosis (2nd-line): 70 mg IV loading, then 50–70 mg IV daily (Some use 70 mg daily for aspergillosis — NCCN note)
Same as anidulafungin
• FDA-approved for: empiric therapy in neutropenic fever, IA (2nd-line), candidal esophagitis, candidemia • Hepatic dose adjustment: mild (Child-Pugh 5–6): no adjustment; moderate (7–9): reduce maintenance to 35 mg daily; severe: limited data • Renal: no dose adjustment • Notable DDIs: cyclosporine → ↑ caspofungin AUC by 35%; tacrolimus levels may decrease • Rifampin, phenytoin, carbamazepine, dexamethasone → may reduce caspofungin levels (consider 70 mg/day maintenance)
Micafungin [Mycamine®]
Candidemia/invasive candidiasis: 100 mg IV daily Candidal esophagitis: 150 mg IV daily HCT prophylaxis: 50 mg IV daily Aspergillus (2nd-line, some centers): 150 mg IV daily
Same as anidulafungin
• FDA-approved for HCT prophylaxis of candidal infections (unique vs other echinocandins) • No hepatic or renal dose adjustment • DDI concern: sirolimus → increased sirolimus levels; nifedipine levels may increase • Most studied echinocandin in pediatrics
Rezafungin [Rezzayo®] — NEWEST
Candidemia/invasive candidiasis: 400 mg IV x 1 dose (Week 1 loading), then 200 mg IV once WEEKLY
Candida spp. — including C. auris and some fluconazole-resistant strains
• NCCN: Category 1 for patients with limited or no alternative treatment options for candidemia/invasive candidiasis (ReSTORE trial) • NOT a first-line replacement for all patients — reserved for those with limited alternatives per NCCN • Once-WEEKLY dosing is unique — confirms adherence but also means error correction takes longer • Approved for adults only; limited data in neutropenic/immunocompromised • No hepatic or renal dose adjustment studied sufficiently
CRITICAL ECHINOCANDIN CLASS POINTS (NCCN + IDSA) • Echinocandins have POOR CNS, urinary tract, and eye penetration → DO NOT use for: fungal meningitis, endophthalmitis, UTI with Candida (use fluconazole for susceptible strains instead). • For candidal ESOPHAGITIS: use echinocandin only if refractory to oral therapy or unable to take PO — not first-line for esophagitis (fluconazole preferred orally). • C. auris: may be resistant to echinocandins — check susceptibility testing. • Three classic agents (micafungin, caspofungin, anidulafungin) are considered interchangeable per NCCN — but NOTE: only micafungin has HCT prophylaxis FDA indication; only caspofungin has empiric neutropenic fever indication.
THERAPEUTIC DRUG MONITORING (TDM)
Drug
TDM Indicated?
Target Trough Level
When to Draw
Clinical Implication of Out-of-Range
Voriconazole
YES — routinely (NCCN)
1–5.5 mcg/mL (NCCN: ≥1–2 mcg/mL minimum for efficacy)
At steady state: ~5–7 days after starting Or 1 week after initiation
Low levels: poor absorption (common with capsule + acid suppression). Switch to solution or consider alternative.
Isavuconazole
NOT routinely (NCCN)
No established target
N/A for routine monitoring
High variability is less common; TDM may be considered in select cases (failure, toxicity)
Fluconazole
NOT routinely (NCCN)
N/A
N/A
Predictable PK; dose-adjust for renal function
Pharmacist TDM Pearls • Voriconazole: CYP2C19 phenotype variation is clinically significant. Poor metabolizers (common in East Asians) will accumulate drug → more side effects. Extensive metabolizers may have subtherapeutic levels. ALWAYS check TDM at 1 week. • Posaconazole suspension: absorption driven by fat content of meal AND gastric pH. PPIs reduce levels. Recommend DR tablet whenever possible for reliable levels. • Itraconazole capsule vs solution: capsule requires acid for dissolution → takes with cola or acidic food. Solution taken fasting. Do NOT interchange capsule and solution doses. • When TDM shows sub-therapeutic levels: first assess adherence, food intake, drug interactions, formulation before reflexively increasing dose. • Azole toxicity monitoring: LFTs (all azoles), QTc (all except isavuconazole), visual symptoms (voriconazole), skin (voriconazole — SCC with long-term use).
NCCN Note: Azoles as a class have important drug interactions, especially with newer therapeutic agents. Please carefully review. Drug-drug interactions are common and need to be closely monitored (consult package inserts for details). — NCCN FEV-B 1 of 5
Antifungal
Interacting Agent
Mechanism
Clinical Consequence
Management
Mold-active azoles (POS/VOR/ITRA)
Vincristine
CYP3A4 inhibition → ↑ vincristine
SEVERE neurotoxicity (vincristine toxicity — peripheral neuropathy, SIADH)
AVOID. Stop azole several days before vincristine; wait ≥10 days after azole D/C before giving vincristine. Use echinocandin prophylaxis instead.
Avoid if possible; dose-reduce TKI per label (ibrutinib: reduce to 140 mg if on moderate CYP3A4 inhibitor); ID/oncology pharmacist consultation mandatory.
All azoles
Calcineurin inhibitors (cyclosporine, tacrolimus)
CYP3A4 inhibition → ↑ CNI levels
Nephrotoxicity, neurotoxicity
Reduce CNI dose by 50–75% when starting azole; monitor levels closely and dose-adjust.
Voriconazole
Rifampin, rifabutin
CYP induction → ↓ VOR levels
Sub-therapeutic VOR → treatment failure
CONTRAINDICATED with rifampin. Rifabutin reduces VOR levels; avoid co-administration.
Caspofungin
Cyclosporine
Mechanism unclear
↑ Caspofungin AUC by ~35%; possible hepatotoxicity signal
Use with caution; monitor LFTs. Most guidelines state benefit outweighs risk but proceed with monitoring.
Voriconazole
Sirolimus/everolimus
CYP3A4 inhibition → ↑ mTOR inhibitor
Major toxicity (pneumonitis, mucositis, nephrotoxicity)
CONTRAINDICATED. Avoid co-administration.
All azoles
Warfarin
CYP2C9 inhibition → ↑ INR
Bleeding risk
Monitor INR closely; significant dose reduction of warfarin likely needed.
Baseline ECG; serial QTc monitoring; avoid stacking QTc-prolonging agents. Isavuconazole does NOT prolong QTc — consider as alternative.
Fluconazole
Phenytoin, carbamazepine
CYP2C9/3A4 inhibition
↑ phenytoin/carbamazepine → toxicity
Monitor drug levels; dose-adjust anticonvulsants.
NCCN GUIDANCE ON AZOLE-CHEMOTHERAPY INTERACTIONS • CYP3A4 inhibition by azoles can lead to toxicity when administered with proteasome inhibitors, tyrosine kinase inhibitors, and vinca alkaloids. • Mold-active azoles should be STOPPED several days before the potential interacting drug is given. • Azoles should NOT be STARTED until the interacting agent has been discontinued AND sufficient time has elapsed for elimination. • NCCN: some institutions consider waiting at least 10 days following administration of these drug classes before starting azole. • USE ECHINOCANDIN PROPHYLAXIS when azoles are contraindicated due to DDI — consult pharmacy/ID.
MANAGEMENT ALGORITHMS
8.1 Empiric Antifungal Therapy in Persistent Neutropenic Fever
Fluconazole (only if susceptible species and patient is not critically ill) AmB-D or L-AmB if intolerant
≥14 days after last positive blood culture AND resolution of signs/symptoms. Mandatory: repeat blood cx daily until clear; ophthalmology exam; central line removal FAVORED.
Candidemia — neutropenic
Echinocandin (preferred) L-AmB (alternative)
VOR or POS not preferred empirically (insufficient candidal bactericidal data)
≥14 days after neutrophil recovery AND resolution of signs/symptoms + negative blood cultures x ≥14 days.
Candidal esophagitis
Fluconazole 200 mg PO/IV daily x 14–21 days (preferred)
Echinocandin (for refractory/unable to take PO) Voriconazole (alternatives)
Echinocandin is NOT first-line for esophagitis unless truly unable to take PO or fluconazole-refractory.
Oropharyngeal candidiasis (thrush)
Fluconazole 100–200 mg PO daily x 7–14 days OR topical clotrimazole troches
Posaconazole, voriconazole, or echinocandin (if fluconazole-refractory)
Topical options first if mild; systemic if moderate-severe.
Hepatosplenic candidiasis
Echinocandin (initial) Step-down to fluconazole if susceptible
Isavuconazole — non-inferior to VOR (SECURE trial; Cat 1) L-AmB 3–5 mg/kg/day (Cat 2A — alternative) Combination VOR + echinocandin: limited evidence (Marr 2015 — benefit in select patients)
Minimum 12 weeks (NCCN, IDSA); continue through immunosuppression Step-down VOR IV → PO when clinically stable (PO bioavailability ~96%)
CNS Aspergillosis
Voriconazole (primary) 35% complete/partial response in retrospective data
L-AmB (AmB-D rarely reaches CNS) Combination: VOR + echinocandin in select cases
Prolonged; monitor TDM closely Neurosurgery consult for accessible lesions
Refractory/intolerant of VOR
L-AmB 3–5 mg/kg/day OR Posaconazole (salvage) OR Isavuconazole OR Echinocandin (2nd-line; not monotherapy for IA)
Combination therapy at some centers
Salvage: response rates ~40–50%
A. terreus Infection
Voriconazole or Isavuconazole (intrinsically resistant to AmB)
Echinocandin (limited data)
CRITICAL: A. terreus is INTRINSICALLY resistant to AmB — AmB will FAIL
⚠ Voriconazole has ZERO activity against Mucorales. Breakthrough mucormycosis is a recognized complication of VOR prophylaxis/therapy — suspect Mucor when patient worsens on VOR despite adequate levels.
8.4 Mucormycosis Management
Most rapidly fatal IFI; requires immediate multi-pronged approach.
Treatment Principles:
SURGICAL DEBRIDEMENT: early and aggressive — mandatory whenever feasible. Surgery is a critical component; antifungals alone are often insufficient.
Antifungal: L-AmB 5 mg/kg/day IV (first-line; NCCN recommends lipid formulation over AmB-D to reduce nephrotoxicity)
Step-down / maintenance (after control of infection + debridement): Isavuconazole OR Posaconazole (NCCN)
Posaconazole: NOT FDA-approved for mucormycosis (but NCCN endorses as maintenance/salvage)
Isavuconazole: FDA-approved for invasive mucormycosis (VITAL trial — single-arm; 33% all-cause mortality vs 39% matched controls on AmB)
Optimize host: control hyperglycemia (DKA), reduce/eliminate corticosteroids if possible, reverse immunosuppression where feasible, manage iron overload
What DOES NOT WORK:
⚠ Voriconazole — NO activity against Mucorales
⚠ Fluconazole, itraconazole — NO activity against Mucorales
⚠ Echinocandins alone — minimal activity; not standard of care as monotherapy for Mucorales
Dose-reduce or extend interval for CrCl <50 mL/min
KEY CLINICAL TRIALS (BRIEF SUMMARIES)
Trial
Population
Intervention vs Comparator
Key Results
Implication
Herbrecht et al. N Engl J Med 2002
Invasive aspergillosis (primary therapy)
Voriconazole IV/PO vs Amphotericin B deoxycholate
VOR: 53% success rate vs 32% AmB-D (p<0.05) 12-week survival: 71% VOR vs 58% AmB-D (HR 0.59) More responses with VOR in neutropenic subgroup
Established VOR as standard of care (Category 1) for primary therapy of IA. NCCN, IDSA, ESCMID all reference this trial.
SECURE Trial (Maertens et al.) Lancet 2016
Invasive mold disease (primarily IA)
Isavuconazole vs Voriconazole (non-inferiority RCT)
All-cause mortality: 19% (ISA) vs 20% (VOR) — non-inferior Isavuconazole had FEWER drug-related AEs; less visual AEs; NO QTc prolongation (actually QTc shortening)
Established isavuconazole as Category 1 alternative to VOR for IA. Preferred when QTc concern or VOR toxicity.
VITAL Trial (Marty et al.) Lancet Infect Dis 2016
Mucormycosis (and rare fungi) (single-arm open-label + matched control analysis)
Isavuconazole (single-arm) vs matched controls on AmB-based therapy
All-cause mortality: 33% (ISA) vs 39% (controls) — not statistically significant (small n) 95% had ≥1 AE, mostly GI
Basis for FDA approval of ISA for invasive mucormycosis. Used when AmB-based therapy is not tolerated or for maintenance.
Posaconazole Prophylaxis (Cornely et al.) N Engl J Med 2007
AML/MDS patients on intensive chemotherapy (neutropenic)
Posaconazole 200 mg TID suspension vs Fluconazole 400 mg daily OR itraconazole 200 mg BID
IFI incidence: 2% (POS) vs 8% (FLU/ITRA) 16-week mortality: 16% vs 22% (p=0.04) IA specifically: 1% vs 7%
Established posaconazole as standard of care (Category 1) for antifungal prophylaxis in AML/MDS induction neutropenia.
Posaconazole in GVHD (Ullmann et al.) N Engl J Med 2007
Allogeneic HCT with GVHD requiring IST
Posaconazole 200 mg TID suspension vs Fluconazole 400 mg daily
IA incidence: 2.3% (POS) vs 6.8% (FLU) (p=0.006) No significant mortality difference POS superior for mold prevention
Supports Category 1 posaconazole prophylaxis in GVHD patients on IST.
AmBiLoad Trial (Cornely et al.) Clin Infect Dis 2007
Invasive mold infections (primarily IA)
L-AmB 10 mg/kg/day (high-loading) vs L-AmB 3 mg/kg/day (standard)
Efficacy equivalent between doses at week 12 High-dose: significantly more nephrotoxicity, hypokalemia, infusion reactions
NCCN: 3 mg/kg L-AmB just as effective as 10 mg/kg for aspergillosis with significantly less toxicity. Supports standard 3 mg/kg dosing. For mucormycosis: some evidence supports higher doses (5 mg/kg).
Mora-Duarte et al. (Caspofungin vs AmB-D) N Engl J Med 2002
Invasive candidiasis (including candidemia)
Caspofungin 70 mg loading → 50 mg daily vs Amphotericin B deoxycholate
Overall success: 73.4% (CAS) vs 61.7% (AmB-D) (p=0.09; numerically favoring CAS) Significantly less nephrotoxicity with caspofungin
Established echinocandin superiority in tolerability for candidemia. Foundation for echinocandin as first-line for candidemia.
ReSTORE Trial (Thompson et al.) Lancet 2023
Adults with candidemia and/or invasive candidiasis
Rezafungin 400 mg loading → 200 mg IV once weekly vs Caspofungin 70 mg → 50 mg IV daily
Global cure at Day 30: 62.4% (RZF) vs 60.7% (CAS) — non-inferior 30-day all-cause mortality: 17.5% vs 21.3%
Led to FDA approval of rezafungin. NCCN Category 1 for patients with limited/no alternative options. Not yet first-line for all candidemia.
Combination VOR + Echinocandin for IA (Marr et al.) Ann Intern Med 2015
Invasive aspergillosis in hematology patients (RCT)
Voriconazole + Anidulafungin vs Voriconazole + placebo
NCCN: evidence for combination remains limited. Some centers use VOR + echinocandin particularly in galactomannan-positive patients; not standard for all IA.
CLINICAL PEARLS — TAKEAWAYS FOR COMPETENCY
11.1 Prophylaxis Pearls
💎 Pearl: Posaconazole (Category 1) is the ONLY mold-active antifungal with Category 1 evidence for AML/MDS induction prophylaxis. Do not accept substitutions without clinical justification.
💎 Pearl: Autologous HCT WITHOUT mucositis = NO antifungal prophylaxis recommended. Adding fluconazole reflexively is NOT guideline-based.
💎 Pearl: When a patient on azole prophylaxis develops fever — their galactomannan will be falsely low due to mold-active agent interference. Never reassure solely based on a negative GM in patients already on azole prophylaxis.
💎 Pearl: Echinocandin (not azole) is the preferred switch when azole-interacting drugs (vincristine, bortezomib, TKIs) are given concurrently. Consult pharmacy/ID proactively before starting these drug combinations.
11.2 Treatment Selection Pearls
💎 Pearl: Mucormycosis = surgical emergency. Medical therapy alone is insufficient. Aggressively advocate for surgical consultation regardless of transplant/neutropenia status.
💎 Pearl: Voriconazole: ZERO activity against Mucorales. Breakthrough mucormycosis should be suspected when a patient on VOR deteriorates despite adequate drug levels. Immediately assess for Mucor.
💎 Pearl: A. terreus is intrinsically resistant to ALL amphotericin B formulations. If culture returns A. terreus and patient is on AmB, it WILL fail — switch to voriconazole or isavuconazole.
💎 Pearl: Isavuconazole is the ONLY antifungal that SHORTENS QTc — making it the preferred choice when the patient has multiple QTc-prolonging agents or baseline QTc prolongation.
💎 Pearl: Echinocandins do NOT penetrate CNS, eyes, or urinary tract — never use alone for fungal meningitis, endophthalmitis, or urinary candidiasis. Fluconazole penetrates all three compartments.
11.3 Dosing & Formulation Pearls
💎 Pearl: Posaconazole oral SUSPENSION: absorption requires high-fat meal AND normal gastric pH. PPIs significantly reduce absorption. SWITCH to DR tablet or IV in any patient on PPI or with GI motility issues.
💎 Pearl: Liposomal AmB (L-AmB) for Aspergillosis: 3 mg/kg is as effective as 10 mg/kg with significantly less toxicity (AmBiLoad). Never order 10 mg/kg for IA without specific justification.
💎 Pearl: Voriconazole IV contains SBECD vehicle — AVOID in CrCl <50 mL/min (SBECD accumulates). Switch to PO voriconazole — bioavailability is ~96% (exceptional).
💎 Pearl: Isavuconazole LOADING: 372 mg q8h x 6 doses over 48 hours → then 372 mg once daily. Many practitioners mistakenly dose this incorrectly. 372 mg isavuconazonium sulfate = 200 mg isavuconazole base.
💎 Pearl: Itraconazole NEGATIVE inotropic effect: AVOID in heart failure. Use alternative (echinocandin or posaconazole) in patients with reduced EF.
11.4 Monitoring & Safety Pearls
💎 Pearl: Always obtain an OPHTHALMOLOGY dilated exam within 1 week of confirmed candidemia — endophthalmitis is silent but changes treatment duration and may require intravitreal antifungal injection.
💎 Pearl: Voriconazole: long-term use (>3 months) is associated with SCC skin cancer, periostitis (bone pain), and hyperphosphatemia due to fluorosis. Counsel patients and monitor annual skin exams.
💎 Pearl: Amphotericin B nephrotoxicity: saline loading (1L NS before infusion) is evidence-based and REDUCES AmB-D nephrotoxicity. Order proactively as standard premedication.
💎 Pearl: Galactomannan interference: ALL mold-active azoles (VOR, POS, ISA) AND echinocandins can reduce serum GM sensitivity. Positive GM in a patient on prophylaxis is even MORE significant — act on it.
CRITICAL PHARMACIST WATCHOUTS
12.1 Drug-Drug Interaction Watchouts
🔴 Watchout: VINCRISTINE + any mold-active azole = CONTRAINDICATED in practice. If you see vincristine on the chemo order with POS, VOR, ITRA — this is a CRITICAL alert. Severe neurotoxicity risk. Escalate immediately.
🔴 Watchout: BORTEZOMIB or IXAZOMIB + VOR/POS = significant CYP3A4 interaction. Dose reduction of PI typically required. Always check with prescriber before dispensing.
🔴 Watchout: IBRUTINIB + VOR/POS = ibrutinib levels may increase 5–10x. FDA label recommends reducing ibrutinib to 140 mg with moderate CYP3A4 inhibitors. Ensure dose adjustment is ordered.
🔴 Watchout: VENETOCLAX + VOR/POS at venetoclax RAMP-UP phase = increased tumor lysis syndrome risk due to elevated venetoclax levels. Interruption of azole recommended during ramp-up per venetoclax label.
🔴 Watchout: RIFAMPIN + VORICONAZOLE = CONTRAINDICATED (rifampin is a powerful CYP inducer → renders voriconazole sub-therapeutic).
🔴 Watchout: TACROLIMUS/CYCLOSPORINE + azoles = tacrolimus levels can increase 3–5 fold. Always flag and reduce CNI dose when adding azole; monitor levels within 48–72h.
12.2 Formulation & Administration Watchouts
🔴 Watchout: Posaconazole SUSPENSION ≠ DR TABLET. They are NOT interchangeable dose for dose. Switching without recognizing the formulation change can result in subtherapeutic levels (suspension) or supratherapeutic levels.
🔴 Watchout: SUBA-itraconazole is NOT interchangeable with other itraconazole products (NCCN FEV-B). Do not substitute generically.
🔴 Watchout: AmB (conventional AmB-D): NEVER infuse faster than 4–6 hours — rapid infusion increases infusion reactions and nephrotoxicity risk. Premedication is mandatory.
🔴 Watchout: Liposomal AmB must be reconstituted with STERILE WATER for injection and diluted in D5W — NOT normal saline (causes precipitation and potential embolism risk).
🔴 Watchout: Voriconazole IV: SBECD vehicle accumulates when CrCl <50 mL/min. Do not dispense IV formulation in these patients — switch to PO (bioavailability ~96%; equally effective).
12.3 Monitoring Watchouts
🔴 Watchout: Obtain voriconazole trough level at 1 WEEK after initiation. Do NOT wait until patient fails clinically. Levels <1 mcg/mL predict treatment failure.
🔴 Watchout: Candidemia: blood cultures must be repeated DAILY until 2 consecutive negatives. Premature culture discontinuation is a major clinical error that delays treatment duration calculation.
🔴 Watchout: Candidemia treatment duration starts from the date of the FIRST NEGATIVE blood culture, NOT from day 1 of antifungal. Clarify this to prescribers — underdosing duration is common.
🔴 Watchout: Echinocandin + CNS fungal infection: echinocandins do NOT achieve therapeutic CNS levels — ensure patient with fungal meningitis/encephalitis is NOT on echinocandin monotherapy.
🔴 Watchout: QTc monitoring: all azoles EXCEPT isavuconazole prolong QTc. If patient has QTc >500ms, escalate to consider isavuconazole, echinocandin, or AmB.
12.4 Counseling Watchouts
🔴 Watchout: Posaconazole suspension counseling: take WITH a full meal or nutritional supplement. If patient is NPO or on a liquid diet — absorption is dramatically reduced. Escalate to IV or DR tablet.
🔴 Watchout: Fluconazole resistance patterns: C. glabrata and C. krusei have reduced susceptibility/intrinsic resistance. Do NOT default to fluconazole without speciation + susceptibility data on a new Candida BSI.
🔴 Watchout: Voriconazole photosensitivity: counsel patients to avoid sun exposure and use sunscreen. Long-term VOR → risk of SCC. Refer to dermatology for annual skin checks.
🔴 Watchout: Amphotericin B: counsel patients on expected infusion reactions (fever, chills, rigors) — these are manageable but alarming if unexpected. Pre-medication protocol should be in place.
SUPPORTIVE CARE IN FUNGAL INFECTIONS
13.1 Amphotericin B Infusion Reaction Management
NCCN FEV-B Note: Infusional toxicity may be managed with antipyretics, an antihistamine, steroid, and meperidine (for rigors).
Standard Premedication Protocol: Acetaminophen 650 mg PO + Diphenhydramine 25–50 mg IV + Hydrocortisone 25–50 mg IV (30 minutes before infusion)
Rigors/chills: Meperidine 25–50 mg IV PRN (short-acting; be cautious in patients with renal failure or seizure history)
Nephroprotection: Saline loading — 1L NS before AmB-D infusion (evidence-based)
Grade infusion rate: typically 4–6 hours for conventional AmB-D; liposomal AmB over 2 hours (with first dose over 4 hours if concerned)
13.2 GCSF / Growth Factor Considerations in Fungal Infection
Note (NCCN Infections Guideline): Recovery from neutropenia is essential for resolution of invasive fungal infections. Growth factors may be considered to shorten neutropenia, particularly in patients with IA or mucormycosis. Refer to NCCN Growth Factors Guideline.
Filgrastim (G-CSF) or pegfilgrastim: may accelerate neutrophil recovery, improving host defense against fungi
GM-CSF (sargramostim): additionally activates macrophages which are critical anti-Aspergillus effectors
WBC transfusion (granulocyte infusion): may be considered in refractory IFI with persistent neutropenia — highly specialized, limited evidence
Voriconazole — ZERO activity Fluconazole — ZERO activity Echinocandin monotherapy
PJP
TMP-SMX IV/PO (DOC) ± steroids if PaO2 <70 mmHg
Pentamidine IV Clindamycin + primaquine
Azoles — NOT effective Echinocandins — NOT effective
Cryptococcus — Meningitis
Amphotericin B (L-AmB preferred) + flucytosine (induction) Then fluconazole consolidation/maintenance
Fluconazole (less severe cases)
Echinocandins — poor efficacy; not standard
Histoplasma — Disseminated
Itraconazole 200 mg TID x 3 days → BID (mild-moderate) L-AmB (severe)
Voriconazole (alternative)
Echinocandins — not standard
FINAL CLINICAL PEARL — The Pharmacist’s Mindset in Fungal Infections 1. ALWAYS know your patient’s antifungal prophylaxis history BEFORE assessing a new fever or new infiltrate — it changes your DDx and your diagnostic test interpretation. 2. ALWAYS check speciation AND susceptibilities before assuming fluconazole will work for Candida — C. glabrata and C. krusei break this assumption. 3. NEVER stop at a negative galactomannan in a patient already on mold-active prophylaxis — the test has reduced sensitivity in this setting. 4. ALWAYS flag azole + QTc-prolonging agent co-prescriptions at chemotherapy review — proactively suggest isavuconazole or echinocandin when QTc concern exists. 5. REMEMBER the triangle: Mucormycosis = Amphotericin B + Surgery + Reversing immunosuppression. No single intervention is sufficient. 6. SOURCE: NCCN Guidelines® for Prevention and Treatment of Cancer-Related Infections, Version 1.2026 (March 11, 2026).